STARD5 and hepatocellular carcinoma: Our prognostic model indicated that Stard5 deficiency in HCC was associated with poor prognosis, and we observed that STARD5 mRNA was markedly decreased in 82% (23/28) of HCC tumors compared to the corresponding adjacent normal liver tissue (Fig. 6a).